Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2025 · 10-Q
Revenue$84.53K$84.53K+63.5% vs Q2 2024 Net Income$369.58K$369.58KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Gross Profit$75,628+37.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$288,370N/M Free Cash Flowderived-$288,370— Margins · derivedGross margin89.5%−16.6 pt vs Q2 2024
Operating margin-343.7%+80.8 pt vs Q2 2024
Net margin437.2%+1147.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Mar 25, 2026 · 268 d after period end